Vaccination was halted in several European countries following reports of blood clotting from the Oxford-AstraZeneca vaccine.
This is a rare form of blood clotting. But the regulator has also said that the benefit from the vaccine is so much that extremely rare cases of blood clotting can be ignored.

Brussels. The Drug Regulator of the European Union has said that it has found a link between the AstraZeneca vaccine and blood clotting. This is a rare way of blood clotting. But the regulator has also said that the benefit from the vaccine is so much that extremely rare cases of blood clotting can be ignored. The European Medicine Agency, in a statement released on Wednesday, did not announce any new restrictions on the use of vaccines for people 18 years and older.

Significantly, the European countries Denmark, Norway and Iceland had put an immediate ban on vaccination with the Oxford-AstraZeneca vaccine. Experts had studied about it. Then the European Union experts said that there were no signs of serious problems like blood clotting from the Oxford-AstraZeneca vaccine. But now the European drug regulator has found links between the two. But these cases are very rare.

India’s experts also appealed not to worry
Earlier, Dr. VK Paul, a member of the NITI Aayog in India, also appealed not to worry about Kovishield. They have made it clear that there is no danger from vaccination. Paul said – the committee of India, which has been monitoring the serious conditions after vaccination, has also denied blood clotting from Kovishield. For the past few days, this committee was constantly monitoring such cases. I assure you that there are no such signs. Serum Institute of India has been a partner in the Oxford-AstraZeneca project and is making this vaccine under the name of Kovishield.

.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *